Merck announced its plan to acquire Acceleron in September, saying it would pay $180 per share in cash.
The acquisition expands Merck’s rare disease drug portfolio, as it allows the company to take over Acceleron’s lead drug candidate, sotatercept. Merck will also gain access to Reblozyl, a drug Acceleron developed to treat anemia in certain rare blood disorders.
“This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy,” Rob Davis, Merck’s CEO and president, said in a statement.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
